Objective. To study the predictive factors for avascular necrosis (AVN ) of bone in patients with systemic lupus erythematosus (SLE).
A necrosis (AVN ) of bone is a major associated AVN in 79 hips from 50 patients with various underlying diseases who had a core decompresmorbidity in systemic lupus erythematosus (SLE ). Corticosteroid usage has been suggested to be the main sion. Eighteen of these patients suffered from SLE. It was demonstrated that late stage of AVN at presentacausative factor for this complication. However, AVN has long been recognized in SLE patients who had not tion (Stage III ) and radiological extent of the lesion (>200 degrees) predicted the progression of AVN, been put on steroid [1, 2] . Zizic and colleagues [3] commented on the rarity of AVN in other steroidregardless of the underlying diagnosis. It is, therefore, necessary to identify those patients who are at risk of dependent patient populations, such as asthma, dermatological diseases and inflammatory bowel disorders, AVN so that early diagnosis of AVN can be made by more sensitive techniques and intervention can be when compared to SLE. This suggests that additional factors specific to SLE itself may be responsible for started at the earliest possible time, when it will be most effective. In this study, we analysed and compared AVN. Recently, the antiphospholipid antibodies have been implicated in the pathogenesis of osteonecrosis in the clinical manifestations, autoantibody profile and corticosteroid doses in patients who developed AVN SLE. Asherson et al. [4] found that anticardiolipin antibodies were more prevalent in patients with AVN during the course of their SLE with those who did not. Logistic regression was used to study the risk than in those without. This result was supported by Nagasawa et al. [5] who demonstrated that SLE factors for AVN. patients with AVN were more likely to be tested positive for the lupus anticoagulant. It is, therefore, PATIENTS AND METHOD likely that multiple aetiological factors are operating Records of 320 patients with SLE who attended our in those SLE patients who developed AVN during the rheumatology and lupus clinics from 1971 to 1997 course of their disease.
were reviewed retrospectively. They all fulfilled at least In our population of SLE patients, AVN is an four of the 1982 American Rheumatology Association important treatment complication and contributes to (ARA) criteria for the classification of SLE [7] and significant morbidity. Most of our patients present late had a disease duration of >18 months. All of the and arthroplasty is the usual final outcome. Mont et al. patients were ethnic Chinese. Cases of symptomatic [6 ] studied the risk factors for progression of steroid-AVN were identified by one or more of the following imaging techniques: plain X-ray, radioisotope bone scan and magnetic resonance imaging (MRI [8] . The SLEDAI scores at the time of are summarized in Table I . Both groups of patients had a comparable age of onset and duration of the maximum steroid dosage were recorded for all the patients studied.
disease. There were more male patients in the AVN group than the control group, although this did not reach statistical significance (13% vs 6%; P = 0.11).
Laboratory evaluation
Antinuclear antibody (ANA) was detected by an Patients with AVN had a higher incidence of central nervous system (CNS ) disease and lupus nephritis, but indirect immunofluorescence method. Anti-doublestranded (ds) DNA antibody was measured using less alopecia and photosensitivity. When the observed P values were adjusted for multiple significance tests, ELISA and Farr assay. Anti-ENA antibodies (Ro, La, Sm, nRNP) were detected using countercurrent only neurological disease was significantly more common in the AVN group (39% vs 14%; P < 0.001). immunoelectrophoresis (CIEP). Lupus anticoagulant was screened by mixing studies, dilute Russell Viper
The SLEDAI scores at the time of maximum corticosteroid dosage were higher in patients with AVN than venom test, kaolin clotting time and platelet neutralization. Anticardiolipin antibodies (IgG and IgM ) were in those without (15.4 vs 13.2; P = 0.10), but this did not reach statistical significance. assayed using a standard ELISA kit from Cambridge Life Sciences. A positive test was defined as a value of Concerning the autoantibodies, the prevalences of anti-dsDNA, various anti-ENA antibodies and anticar->10 IU/ml on at least two occasions >3 months apart. Values between 11 and 20 IU/ml were considered diolipin antibodies in both groups of patients were not significantly different. The IgG and IgM anticardiolipin to be weak positive, while a moderately strong and a strong positive test were defined as values between 21 titres were also similar in both groups. However, patients with AVN had a significantly higher prevalence and 30 IU/ml and >30 IU/ml, respectively. of lupus anticoagulant (27% vs 12%; P = 0.02). Using the x2 analysis, lupus anticoagulant was associated
Statistical analysis
Student's t-test for independent samples was used to with AVN (P = 0.02, odds ratio 2.88 [1.14-7.18]). compare parametric data between the AVN and the control group of patients. The x2 test was used when
Sites of AVN and outcome
The hip (femoral head ) was the commonest site of the data were non-parametric. Yates' continuity correction was adopted whenever the number was small. For involvement of AVN in our SLE patients (36/38, 95%) and bilateral involvement was present in 26 cases multiple significance tests, significance was defined as a P value of <0.01. The trend of AVN risk with (72%). This was followed by involvement of the knee (femoral condyle) (5/38, 13%), the humerus (1/38, 3%) increasing cumulative prednisolone dose received was studied by the x2 test for linear trend. Risk factors for and the carpal bones (1/38, 3%). Five patients had two or more sites of AVN (bilaterality was counted as AVN were studied by stepwise logistic regression using AVN as the outcome variable and other factors such one site). Arthroplasty of the hip was performed for 21 patients because of persistent pain or limitation of as age, sex, disease duration, Cushingoid habitus, steroid dose, duration and route, SLEDAI scores at range of movement. maximum steroid dosage and antiphospholipid antibodies as the predictor variables. Regression coeffi-AVN and corticosteroid administration Table II shows the information regarding corticocients ( b) were calculated. P values of <0.05 were considered significant. steroid administration and other associated medical diseases in the AVN patients and controls. The AVN RESULTS patients had received a higher total cumulative prednisolone dose than the controls, but this was not statistic-
Demographic data and clinical features
Thirty-eight patients with AVN were identified ally significant (17.7 vs 14.1 g; P = 0.22). However, the highest prednisolone doses received in 1 month among 320 SLE patients, giving rise to a point prevalence of 12%. Three patients developed AVN in the and 4 months were significantly higher in the AVN group than the controls. The incidence of AVN showed absence of steroid treatment, one of whom had active disease at the time of AVN. This was a 19-yr-old girl a linear trend with increasing prednisolone dose administered in 1 month and 4 months ( x2 for linear trend, who presented with AVN of the carpal bones 4 months Renal disease is defined as proteinuria of >0.5 g/day or biopsy-proven lupus nephritis. Lymphopenia is defined as a lymphocyte count of <1.0 × 109/l on at least two occasions. Thrombocytopenia is defined as a platelet count of <100 × 109/l. Leucopenia is defined as a white blood cell count of <4 × 109/l. *For multiple significance tests, P values of <0.01 were considered significant. P < 0.01 in both) ( Table III ) . The average daily pared with those who received oral prednisolone only, patients who had been pulsed had received a signifiprednisolone dose was also significantly higher in the AVN patients (15.6 vs 9.3 mg; P < 0.0001). Patients cantly higher cumulative prednisolone dose in the first 1 and 4 months (3.31 vs 1.00 and 5.47 vs 2.79 g, with AVN were more likely to develop Cushingoid body habitus after steroid administration than controls respectively; P < 0.01 in both). However, the incidence of AVN in patients who had received pulse steroid and (79% vs 53%; P = 0.004). Moreover, patients who became Cushingoid after steroid treatment, when comoral steroid was similar [4/20 (20%) in the pulse group vs 34/161 (21%) in the oral group]. AVN was not pared with those who did not, had received a significantly higher prednisolone dosage in the first 1 and 4 associated with pulse steroid treatment using the x2 analysis (P = 0.86). months (1.71 vs 0.68 and 3.99 vs 1.89 g, respectively; P < 0.0001 in both). Regarding the use of cytotoxic agents, a significantly higher proportion of patients Risk factors for AVN Stepwise logistic regression was carried out for the with AVN had received cyclophosphamide treatment than those without. None of our patients were smokers 38 patients with AVN and the 143 controls, with AVN being the outcome variable and age, sex, disease duror drinkers. Hypertension, diabetes mellitus and impaired renal function were not associated with AVN.
ation, Cushingoid habitus, prednisolone dose, duration and route, SLEDAI scores at maximum steroid dosage, Among the 181 SLE patients studied, 20 received i.v. pulse methylprednisolone (500-1000 mg daily for and the antiphospholipid antibodies being the predictor variables. It was found that the highest cumulative 3 days), followed by oral prednisolone. When com- Corticosteroid use is the chief risk factor for AVN x2 for linear trend: P < 0.01 in both.
in SLE. Studies investigating the association of AVN and steroid treatment yielded conflicting results concerning the cumulative steroid dosage, maximum sterthis was not supported by Migliaresi et al. [15] , who failed to find an increased risk of AVN in patients oid dose, route of steroid administration and the duration of steroid treatment. AVN may develop in receiving i.v. pulse steroid therapy. In our study, we have shown that the highest dose patients who received high-dose, short-term steroids, long-term steroids or even after intra-articular injecof corticosteroid administered within 4 months and the maximum steroid dosage, rather than the total tion. Smith et al. [11] and Dimant et al. [12] did not find any association between the total cumulative dose cumulative steroid dose or the duration of steroid therapy, are predictive factors for AVN in SLE. This of steroid, the duration of therapy or the peak steroid dose with AVN. Bergstein et al. [13] described a is consistent with the results published by Abeles et al. [1] who also demonstrated a higher risk of AVN in relationship between AVN and the total cumulative steroid dose, but not with the duration of steroid patients who received a high cumulative steroid dose in the first and first 3 months after starting steroid treatment. Moreover, whether steroid-induced AVN occurs slowly over a long period of time, or abruptly therapy, when compared with controls. A recent study on the risk factors for AVN in patients with SLE by after a brief period of high-dose treatment, remains controversial. Massardo et al. [14] considered i.v. pulse
Mont et al. [9] also described the peak prednisolone dose as a significant and independent predictive factor methylprednisolone as a risk factor for AVN. However, for AVN. Although pulse methylprednisolone contribof younger age at disease onset, leucopenia, Raynaud's phenomenon or cutaneous vasculitis with AVN, as utes significantly to a higher cumulative steroid dose during the first few months of therapy, we are unable suggested by previous authors. The antiphospholipid antibodies have recently been to show an association of i.v. pulse steroid and AVN. Moreover, logistic regression fails to demonstrate the associated with AVN in patients with SLE. Asherson et al. [4] showed that the prevalence of the antiphosimportance of the route of steroid administration in determining AVN. Two possible explanations can be pholipid antibodies (anticardiolipin antibodies or lupus anticoagulant) was higher in patients with AVN than offered. First, the number of patients who received pulse methylprednisolone is too small for comparison in those without. Although both the AVN and the non-AVN groups were receiving corticosteroid treatwith those who received oral prednisolone, leading to a type II statistical error. Secondly, as the proportion ment, the antiphospholipid antibodies were postulated to be an additional risk factor for AVN in SLE. This of patients who received pulse steroid in both the AVN and control groups of SLE patients is similar (11% in is in agreement with the study by Nagasawa et al. [5] , who investigated 111 SLE patients and reported that both), the higher cumulative prednisolone doses in the first and first 4 months of therapy in the AVN group a demonstrable lupus anticoagulant as well as a shortened partial thromboplastin time (APTT ) were may have represented a higher oral prednisolone dose used instead of pulse methylprednisolone per se.
more common in patients with AVN. Vascular occlusion or a thrombotic vasculopathy related to the AVN has long been reported in SLE patients who had not been taking corticosteroid. Both Leventhal antiphospholipid antibodies was thought to be the underlying aetiological mechanism. In our study, et al. [16 ] and Velayos et al. [17] found evidence of previous vasculitis in pathological bone specimens from the prevalence and the mean titres of the IgG and IgM anticardiolipin antibodies in both the AVN and the patients with SLE not receiving corticosteroid therapy. This leads to postulation that active SLE itself may be control groups of patients were similar. However, a significantly higher prevalence of lupus anticoagulant another predisposing factor for AVN. This is supported by the fact that one of our patients developed AVN at was found in patients with AVN. Using the x2 analysis, lupus anticoagulant was associated with AVN. Logistic the time of active SLE, in the absence of steroid treatment [18] . As her antiphospholipid antibodies regression also confirmed that the lupus anticoagulant was an independent risk factor for AVN. Two of the were repeatedly negative, a localized vasculitic process was thought to be a possible mechanism. Although the three SLE patients in our series who developed AVN in the absence of steroid treatment were positive for SLEDAI scores during the time of maximum steroid dosage in our patients with AVN were higher than both the lupus anticoagulant and anticardiolipin antibodies. This stresses the importance of antiphosphothose in patients without AVN, the difference was not statistically significant. Moreover, regression analysis lipid antibodies in predisposition to AVN.
In conclusion, we believe that the aetiology of AVN does not show that disease activity is a risk factor for AVN. This suggests that the higher initial steroid dose in SLE is multifactorial. Corticosteroid remains the chief predisposing factor for AVN in SLE patients and for the treatment of more active disease in our AVN group of SLE patients is likely to be more relevant its use should be judicious. High-dose steroid administered within the first 4 months, the peak and the mean than the disease activity per se in the contribution to AVN. daily prednisolone dosage, and a positive lupus anticoagulant, are independent risk factors for AVN. A number of clinical features have been described in association with AVN in SLE. These include young Patients with SLE who require a high initial dose of corticosteroid for disease control are at risk of AVN, age of disease onset [11] , Raynaud's phenomenon [19, 20] , Cushingoid habitus after steroid treatment [9, 19] , especially if they are positive for the lupus anticoagulant or become Cushingoid after steroid treatment. vasculitis [9, 17, 19] , thrombophlebitis, smoking, preeclampsia [9] and leucopenia [20] . In our series
More sensitive techniques, such as the radioisotope bone scan and MRI, should be considered for the early of SLE patients, we confirm the observation that Cushingoid habitus after steroid treatment is associated diagnosis of AVN in this group of high-risk patients. with AVN. Patients who became Cushingoid had R received a significantly higher dose of steroid in the first and first 4 months of therapy. This suggests that
